Pemivibart: meta-analysis of COVID-19 studies
Meta-analysis of pemivibart COVID-19 studies. Efficacy is variant dependent. In Vitro research shows reduced efficacy against KP.3.1.1, KP.1.1, LB.1, KP.3.3, and XEC variants1-4. mAb use may create new variants that spread globally5-7, and may be associated with prolonged viral loads, clinical deterioration, and immune escape6,8-11 .
All studies
Mortality
Hospitalization
Serious outcomes
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes
References
Xie et al., Molecular Basis of High-Blood-Pressure-Enhanced and High-Fever-Temperature-Weakened Receptor-Binding Domain/Peptidase Domain Binding: A Molecular Dynamics Simulation Study, International Journal of Molecular Sciences, doi:10.3390/ijms26073250.
Wang et al., Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages, New England Journal of Medicine, doi:10.1056/NEJMc2410203.
Yao et al., Neutralizing Activity and Viral Escape of Pemivibart by SARS-CoV-2 JN.1 sublineages, bioRxiv, doi:10.1101/2024.11.08.622746.
Planas et al., Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies, Pathogens and Immunity, doi:10.20411/pai.v10i1.752.
Focosi et al., Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment, Drug Resistance Updates, doi:10.1016/j.drup.2023.100991.
Leducq et al., Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies, The Journal of Infectious Diseases, doi:10.1093/infdis/jiad523.
Bruhn et al., Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies, eBioMedicine, doi:10.1016/j.ebiom.2025.105770.
Choudhary et al., Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy, medRxiv, doi:10.1101/2021.09.03.21263105.
Günther et al., Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection, medRxiv, doi:10.1101/2024.01.06.24300890.